Evaxion A/S Business Summary

Evaxion A/S (EVAX) is a clinical-stage TechBio company that generates revenue through a multi-partner model involving strategic licensing agreements, milestone payments, and research grants. The company’s business model is anchored by its proprietary AI-Immunology™ platform, which utilizes machine learning to decode the human immune system for high-precision vaccine discovery. Its primary business segments include Oncology, led by the personalized cancer vaccine EVX-01 and the off-the-shelf candidate EVX-04, and Infectious Diseases, which includes the EVX-B3 program out-licensed to MSD and the EVX-B4 prophylactic candidate. Evaxion competes directly with immunotherapy and vaccine developers such as BioNTech, Moderna, IO Biotech, and Cue Biopharma. Within this competitive landscape, Evaxion positions itself as a specialized discovery engine, leveraging its AI platform to achieve superior neoantigen prediction accuracy and durable clinical response rates compared to traditional discovery methods. The company is led by Chief Executive Officer Dr. Helen Tayton-Martin, a molecular immunologist and co-founder of Adaptimmune who brings over 30 years of experience in biotech leadership and strategic deal-making. The executive team also includes Chief Scientific Officer Birgitte Rønø, who has been instrumental in the development of the AI-Immunology™ platform, and Chief Financial Officer Thomas Schmidt, who manages the firm’s capital strategy and recent debt-to-equity conversions. Evaxion’s board is chaired by Marianne Søgaard and features strategic backing from notable institutional investors including Merck & Co. (MSD), Armistice Capital, and the European Investment Bank. This leadership pedigree, supported by grants from the Gates Foundation, underscores the company's transition toward a commercially-oriented partner for global pharmaceutical leaders, supported by a cash runway extending into the second half of 2027.